Marinus Pharmaceuticals (MRNS) Stock Forecast, Price Target & Predictions
MRNS Stock Forecast
Marinus Pharmaceuticals stock forecast is as follows: an average price target of $6.00 (represents a 2464.10% upside from MRNS’s last price of $0.23) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
MRNS Price Target
The average price target for Marinus Pharmaceuticals (MRNS) is $6.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 2464.10% upside from MRNS's last price of $0.23.
MRNS Analyst Ratings
According to 5 Wall Street analysts, Marinus Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for MRNS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Marinus Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Jay Olson | Oppenheimer | $6.00 | $1.67 | 259.28% | 2464.10% |
| Apr 16, 2024 | Brian Skorney | Robert W. Baird | $2.00 | $1.30 | 53.85% | 754.70% |
| Apr 15, 2024 | Sector Perform | RBC Capital | $3.00 | $1.42 | 112.01% | 1182.05% |
| Mar 28, 2024 | Jay Olson | Oppenheimer | $9.00 | $9.04 | -0.44% | 3746.15% |
The latest Marinus Pharmaceuticals stock forecast, released on Sep 23, 2024 by Jay Olson from Oppenheimer, set a price target of $6.00, which represents a 259.28% increase from the stock price at the time of the forecast ($1.67), and a 2464.10% increase from MRNS last price ($0.23).
Marinus Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $6.00 | $5.00 |
| Last Closing Price | $0.23 | $0.23 | $0.23 |
| Upside/Downside | -100.00% | 2464.10% | 2036.75% |
In the current month, the average price target of Marinus Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Marinus Pharmaceuticals's last price of $0.23. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 24, 2024 | JMP Securities | Market Perform | Downgrade | |
| Sep 23, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 23, 2024 | Oppenheimer | Underperform | Outperform | Upgrade |
| Aug 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 07, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| May 07, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Apr 16, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Apr 16, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Apr 15, 2024 | RBC Capital | Outperform | Sector Perform | Downgrade |
| Mar 28, 2024 | Oppenheimer | Perform | Perform | Hold |
| Mar 08, 2023 | RBC Capital | Outperform | Outperform | Hold |
Marinus Pharmaceuticals's last stock rating was published by JMP Securities on Oct 24, 2024. The company Downgrade its MRNS rating from "null" to "Market Perform".
Marinus Pharmaceuticals Financial Forecast
Marinus Pharmaceuticals Revenue Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $7.34M | $6.08M | $10.38M | $7.16M | $2.34M | $1.79M | $14.19M | $1.52M | $10.11M |
| Avg Forecast | $65.70M | $63.17M | $63.17M | $60.65M | $34.71M | $33.37M | $33.37M | $32.04M | $12.85M | $12.36M | $12.36M | $11.86M | $13.43M | $10.20M | $9.22M | $8.39M | $11.34M | $9.42M | $9.58M | $9.04M | $8.01M | $6.32M | $5.73M | $5.78M | $9.15M | $25.76M | $2.28M | $2.27M | $3.37M | $5.16M |
| High Forecast | $78.97M | $75.93M | $75.93M | $72.89M | $41.72M | $40.11M | $40.11M | $38.51M | $15.45M | $14.85M | $14.85M | $14.26M | $16.14M | $12.26M | $11.09M | $9.17M | $18.08M | $11.32M | $9.58M | $9.04M | $9.76M | $6.34M | $6.89M | $6.95M | $11.00M | $25.76M | $2.28M | $2.27M | $3.37M | $5.16M |
| Low Forecast | $56.06M | $53.91M | $53.91M | $51.75M | $29.62M | $28.48M | $28.48M | $27.34M | $10.97M | $10.54M | $10.54M | $10.12M | $11.46M | $8.70M | $7.87M | $7.33M | $8.83M | $8.04M | $9.58M | $9.04M | $6.90M | $6.30M | $4.89M | $4.93M | $7.81M | $25.76M | $2.28M | $2.27M | $3.37M | $5.16M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.16% | 1.06% | 1.80% | 0.78% | 0.09% | 0.78% | 6.24% | 0.45% | 1.96% |
Marinus Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 8 analysts is $8.01M, with a low forecast of $6.90M, and a high forecast of $9.76M. MRNS's average Quarter revenue forecast represents a 9.09% increase compared to the company's last Quarter revenue of $7.34M (Sep 23).
Marinus Pharmaceuticals EBITDA Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-31.65M | $-31.44M | $-30.58M | $-28.98M | $77.83M | $-36.68M | $-17.58M | $-27.02M | $-18.74M |
| Avg Forecast | $-28.90M | $-27.79M | $-27.79M | $-26.68M | $-15.27M | $-14.68M | $-14.68M | $-14.09M | $-5.65M | $-5.44M | $-5.44M | $-5.22M | $-5.91M | $-4.49M | $-4.06M | $-3.69M | $-4.99M | $-4.14M | $-4.21M | $-3.98M | $-3.52M | $-2.78M | $-2.52M | $-2.54M | $-4.02M | $-11.47M | $-1.02M | $-24.41M | $-1.50M | $-2.30M |
| High Forecast | $-24.66M | $-23.71M | $-23.71M | $-22.77M | $-13.03M | $-12.53M | $-12.53M | $-12.03M | $-4.82M | $-4.64M | $-4.64M | $-4.45M | $-5.04M | $-3.83M | $-3.46M | $-3.23M | $-3.88M | $-3.54M | $-4.21M | $-3.98M | $-3.04M | $-2.77M | $-2.15M | $-2.17M | $-3.43M | $-11.47M | $-1.02M | $-19.53M | $-1.50M | $-2.30M |
| Low Forecast | $-34.74M | $-33.40M | $-33.40M | $-32.07M | $-18.35M | $-17.65M | $-17.65M | $-16.94M | $-6.80M | $-6.53M | $-6.53M | $-6.27M | $-7.10M | $-5.39M | $-4.88M | $-4.03M | $-7.95M | $-4.98M | $-4.21M | $-3.98M | $-4.30M | $-2.79M | $-3.03M | $-3.06M | $-4.84M | $-11.47M | $-1.02M | $-29.29M | $-1.50M | $-2.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.39% | 12.47% | 12.03% | 7.20% | -6.79% | 36.13% | 0.72% | 18.03% | 8.16% |
4 analysts predict MRNS's average Quarter EBITDA for Dec 22 to be $-4.02M, with a high of $-3.43M and a low of $-4.84M. This is -105.17% lower than Marinus Pharmaceuticals's previous annual EBITDA (Sep 22) of $77.83M.
Marinus Pharmaceuticals Net Income Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-32.97M | $-33.47M | $-34.57M | $-34.31M | $73.29M | $-42.09M | $-21.05M | - | $-19.51M |
| Avg Forecast | $34.57M | $34.72M | $36.26M | $13.20M | $4.43M | $4.86M | $5.49M | $4.76M | $-5.51M | $-4.61M | $-3.87M | $-4.51M | $-5.46M | $-7.89M | $-10.04M | $-11.17M | $-16.98M | $-23.42M | $-33.79M | $-37.93M | $-35.67M | $-37.82M | $-41.55M | $-41.84M | $-35.51M | $24.79M | $-25.30M | $-26.88M | $-43.43M | $-37.32M |
| High Forecast | $43.65M | $43.83M | $45.78M | $16.66M | $5.59M | $6.13M | $6.94M | $6.00M | $-4.46M | $-3.73M | $-3.14M | $-3.65M | $-4.42M | $-6.39M | $-8.12M | $-3.94M | $-11.12M | $-18.95M | $-27.34M | $-30.69M | $-34.00M | $-30.61M | $-33.63M | $-33.86M | $-28.74M | $24.79M | $-25.30M | $-21.50M | $-43.43M | $-37.32M |
| Low Forecast | $27.98M | $28.09M | $29.35M | $10.68M | $3.58M | $3.93M | $4.45M | $3.85M | $-6.95M | $-5.82M | $-4.89M | $-5.69M | $-6.90M | $-9.96M | $-12.67M | $-17.08M | $-21.66M | $-29.57M | $-42.66M | $-47.89M | $-36.78M | $-47.75M | $-52.46M | $-52.83M | $-44.83M | $24.79M | $-25.30M | $-32.25M | $-43.43M | $-37.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.87% | 0.81% | 0.83% | 0.97% | 2.96% | 1.66% | 0.78% | - | 0.52% |
Marinus Pharmaceuticals's average Quarter net income forecast for Dec 22 is $-35.51M, with a range of $-44.83M to $-28.74M. MRNS's average Quarter net income forecast represents a -148.45% decrease compared to the company's last Quarter net income of $73.29M (Sep 22).
Marinus Pharmaceuticals SG&A Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $14.87M | $15.72M | $15.20M | $14.66M | $13.39M | $17.06M | $11.74M | $10.62M | $9.45M |
| Avg Forecast | $242.17M | $232.86M | $232.86M | $223.55M | $127.94M | $123.02M | $123.02M | $118.10M | $47.37M | $45.55M | $45.55M | $43.73M | $49.51M | $37.60M | $34.00M | $30.92M | $41.81M | $34.73M | $35.31M | $33.32M | $29.51M | $23.29M | $21.13M | $21.31M | $33.72M | $94.95M | $8.41M | $8.38M | $12.41M | $19.01M |
| High Forecast | $291.08M | $279.89M | $279.89M | $268.69M | $153.78M | $147.86M | $147.86M | $141.95M | $56.94M | $54.75M | $54.75M | $52.56M | $59.51M | $45.19M | $40.87M | $33.79M | $66.64M | $41.74M | $35.31M | $33.32M | $35.99M | $23.35M | $25.39M | $25.61M | $40.53M | $94.95M | $8.41M | $8.38M | $12.41M | $19.01M |
| Low Forecast | $206.65M | $198.70M | $198.70M | $190.75M | $109.17M | $104.97M | $104.97M | $100.77M | $40.42M | $38.87M | $38.87M | $37.31M | $42.25M | $32.08M | $29.01M | $27.03M | $32.53M | $29.64M | $35.31M | $33.32M | $25.45M | $23.22M | $18.03M | $18.18M | $28.78M | $94.95M | $8.41M | $8.38M | $12.41M | $19.01M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.64% | 0.74% | 0.71% | 0.43% | 0.14% | 2.03% | 1.40% | 0.86% | 0.50% |
Marinus Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $29.51M, based on 8 Wall Street analysts, with a range of $25.45M to $35.99M. The forecast indicates a 98.47% rise compared to MRNS last annual SG&A of $14.87M (Sep 23).
Marinus Pharmaceuticals EPS Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.61 | $-0.00 | $-0.67 | $-0.76 | $1.93 | $-1.13 | $-0.57 | - | $-0.53 |
| Avg Forecast | $0.60 | $0.61 | $0.63 | $0.23 | $0.08 | $0.08 | $0.10 | $0.08 | $-0.10 | $-0.08 | $-0.07 | $-0.08 | $-0.10 | $-0.14 | $-0.18 | $-0.20 | $-0.30 | $-0.41 | $-0.59 | $-0.66 | $-0.62 | $-0.66 | $-0.73 | $-0.73 | $-0.62 | $0.43 | $-0.44 | $-0.84 | $-0.76 | $-0.65 |
| High Forecast | $0.76 | $0.77 | $0.80 | $0.29 | $0.10 | $0.11 | $0.12 | $0.10 | $-0.08 | $-0.07 | $-0.05 | $-0.06 | $-0.08 | $-0.11 | $-0.14 | $-0.07 | $-0.19 | $-0.33 | $-0.48 | $-0.54 | $-0.59 | $-0.53 | $-0.59 | $-0.59 | $-0.50 | $0.43 | $-0.44 | $-0.84 | $-0.76 | $-0.65 |
| Low Forecast | $0.49 | $0.49 | $0.51 | $0.19 | $0.06 | $0.07 | $0.08 | $0.07 | $-0.12 | $-0.10 | $-0.09 | $-0.10 | $-0.12 | $-0.17 | $-0.22 | $-0.30 | $-0.38 | $-0.52 | $-0.75 | $-0.84 | $-0.64 | $-0.83 | $-0.92 | $-0.92 | $-0.78 | $0.43 | $-0.44 | $-0.84 | $-0.76 | $-0.65 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 0.00% | 0.92% | 1.22% | 4.44% | 2.55% | 0.68% | - | 0.81% |
According to 4 Wall Street analysts, Marinus Pharmaceuticals's projected average Quarter EPS for Dec 22 is $-0.62, with a low estimate of $-0.78 and a high estimate of $-0.50. This represents a -132.15% decrease compared to MRNS previous annual EPS of $1.93 (Sep 22).
Marinus Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| MRNS | Marinus Pharmaceuticals | $0.25 | $6.00 | 2300.00% | Buy |
| IMRX | Immuneering | $1.73 | $17.50 | 911.56% | Buy |
| CABA | Cabaletta Bio | $2.75 | $16.33 | 493.82% | Buy |
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| OVID | Ovid Therapeutics | $1.06 | $3.00 | 183.02% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| VKTX | Viking Therapeutics | $46.70 | $97.80 | 109.42% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.28 | $8.25 | 92.76% | Buy |
| AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
| ELVN | Enliven Therapeutics | $24.39 | $39.50 | 61.95% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| ETNB | 89bio | $7.98 | $12.00 | 50.38% | Buy |
| CNTB | Connect Biopharma | $1.06 | $1.50 | 41.51% | Buy |
| MIRM | Mirum Pharmaceuticals | $42.65 | $57.00 | 33.65% | Buy |
| MDGL | Madrigal Pharmaceuticals | $306.08 | $315.75 | 3.16% | Buy |
| IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |